Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301

NCT03043651 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.

NCT NCT03043651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03043651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Lead sponsor
United Therapeutics
Phase
Phase 3
Overall status
Terminated
Start date
January 30, 2018
Completion date
March 2, 2020
Enrollment
48 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary hypertension associated with hfpef